BridgeBio: "FDA Requests Additional Experiments Before Phase 2 Clinical Trial of 'BBT-877'"

[Asia Economy Reporter Lee Seon-ae] Bridge Biotherapeutics announced on the 28th that the U.S. Food and Drug Administration (FDA) requested additional tests, including toxicity tests, before entering Phase 2 clinical trials for the idiopathic pulmonary fibrosis drug candidate 'BBT-877.' As a result, Bridge Bio's hoped-for immediate entry into Phase 2 has become difficult.

This content was produced with the assistance of AI translation services.